1 . The development of neutralizing antibodies against the flavivirus envelope (E) protein is critical for immunity and vaccine protection 2 . Previously identified candidate therapeutic mouse and human neutralizing monoclonal antibodies (mAbs) target epitopes within the E domain III lateral ridge and the domain I-II hinge region, respectively 3 . To explore the neutralizing antibody repertoire elicited by WNV infection for potential therapeutic application, we isolated ten mAbs from WNVinfected individuals. mAb WNV-86 neutralized WNV with a 50% inhibitory concentration of 2 ng ml -1 , one of the most potently neutralizing flavivirus-specific antibodies ever isolated. WNV-86 targets an epitope in E domain II, and preferentially recognizes mature virions lacking an uncleaved form of the chaperone protein prM, unlike most flavivirus-specific antibodies 4 . In vitro selection experiments revealed a neutralization escape mechanism involving a glycan addition to E domain II. Finally, a single dose of WNV-86 administered two days post-infection protected mice from lethal WNV challenge. This study identifies a highly potent human neutralizing mAb with therapeutic potential that targets an epitope preferentially displayed on mature virions.
West Nile virus (WNV), a member of the Flavivirus genus, is a leading cause of viral encephalitis in the United States 1 . The development of neutralizing antibodies against the flavivirus envelope (E) protein is critical for immunity and vaccine protection 2 . Previously identified candidate therapeutic mouse and human neutralizing monoclonal antibodies (mAbs) target epitopes within the E domain III lateral ridge and the domain I-II hinge region, respectively 3 . To explore the neutralizing antibody repertoire elicited by WNV infection for potential therapeutic application, we isolated ten mAbs from WNVinfected individuals. mAb WNV-86 neutralized WNV with a 50% inhibitory concentration of 2 ng ml -1 , one of the most potently neutralizing flavivirus-specific antibodies ever isolated. WNV-86 targets an epitope in E domain II, and preferentially recognizes mature virions lacking an uncleaved form of the chaperone protein prM, unlike most flavivirus-specific antibodies 4 . In vitro selection experiments revealed a neutralization escape mechanism involving a glycan addition to E domain II. Finally, a single dose of WNV-86 administered two days post-infection protected mice from lethal WNV challenge. This study identifies a highly potent human neutralizing mAb with therapeutic potential that targets an epitope preferentially displayed on mature virions.
Flaviviruses are arthropod-borne, enveloped, positive-stranded RNA viruses that include clinically relevant pathogens such as WNV, dengue virus, yellow fever virus and Zika virus. The development of neutralizing antibodies (NAbs) is a surrogate of protection for most licensed flavivirus vaccines 3 . For emerging flaviviruses such as WNV and Zika virus, licensed vaccines or therapeutic agents for use in humans are lacking.
The main target of flavivirus NAbs is the E protein, which mediates entry into cells, and consists of three structural domains (DI, DII, DIII), a helical stem and two antiparallel transmembrane helices. Although cryo-electron microscopic reconstructions of mature flavivirus particles reveal a smooth surface densely covered with 90 E dimers that lie flat against the viral membrane 3 , flaviviruses are structurally heterogeneous, owing partly to an inefficient cleavage of the viral chaperone protein prM during virion maturation 5 . Unlike the smooth surfaces of mature particles, immature particles incorporate prM-E heterotrimeric spikes, whereas partially mature particles contain structural features of both immature and mature particles 5 . Compared to mature virions containing little or no uncleaved prM, partially mature virions that retain prM are generally more sensitive to neutralization by antibodies targeting poorly exposed epitopes 4, [6] [7] [8] . Several groups have investigated the therapeutic potential of humanized or human mAbs 9, 10 and antibody fragments against WNV 11 . For example, the humanized murine mAb E16 12 demonstrates therapeutic efficacy 9 and recognizes an accessible epitope in the lateral ridge of E DIII (DIII-LR) 13 , a common target of potently neutralizing murine mAbs 3 . However, for some flaviviruses, DIII-LR is not a major target of potently neutralizing human NAbs, which often bind quaternary surfaces comprised of multiple E proteins 3 . Here, we identified a potently neutralizing WNV-specific human mAb that targets an epitope in DII, preferentially recognizes mature particles lacking prM and prevents mortality in mice when administered as a single dose post-infection with WNV.
We obtained 13 matched serum and blood cell samples from individuals in Dallas, Texas with previous laboratory-confirmed symptomatic WNV infection that occurred during the 2012 outbreak 14 . We screened serum samples for neutralization of WNV reporter virus particles (RVPs) 15 ( Fig. 1a,b ) and estimated the reciprocal serum dilution that inhibited infectivity by 50% (NT 50 ). These samples displayed a range of neutralizing activities (median NT 50 of 1,504), with 9 of 13 samples displaying potent neutralization (NT 50 > 1,000). To identify antibodies that mediated serum neutralization, we selected B cells from three donors with potent serum neutralizing activity for the generation of human hybridomas secreting WNV-specific mAbs that were screened for reactivity to WNV E protein. Ten WNV-reactive antibody-secreting hybridoma clones were recovered (Supplementary Table 1 ). Of these, three mAbs (WNV-61, WNV-39, WNV-18) lacked neutralizing activity, and another three (WNV-6, WNV-13, WNV-15) had modest inhibitory activity, with a large fraction (30-50%) of RVPs remaining infectious
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at the highest mAb concentration tested (10 μ g ml -1 ; Fig. 1c,e) . The remaining four mAbs (WNV-10, WNV-57, WNV-62, WNV-86) strongly neutralized WNV RVPs and fully infectious WNV in a flavivirus type-specific pattern, although complete inhibition of WNV was only observed with WNV-86 (Fig. 1c-f and Supplementary  Figs. 1-2 ). WNV-86 was particularly potent, neutralizing 50% of virus infectivity at a concentration (50% inhibitory concentration, IC 50 ) of 2 ng ml -1 , which is lower than that of the therapeutic mAb E16 9, 12 . Similar to murine E16 (mE16), WNV-86 inhibited infection as a Fab fragment ( Supplementary Fig. 3 ) and was capable of blocking infection at a post-attachment step ( Supplementary Fig. 4 ). Binding studies using recombinant E or DIII fragment protein demonstrated that the epitope recognized by these mAbs was located in DI or DII and therefore distinct from the DIII-LR epitope of mAb E16, and did not require a quaternary arrangement of E proteins on the virion surface ( Supplementary Fig. 5 ).
To determine whether virion maturation state affected the activity of the mAbs, we compared their ability to neutralize prM -or prM + WNV RVPs. As previously shown, the DIII-LR-specific murine mAb E16 neutralized these particles with similar potency 4 ( Fig. 2a) , whereas murine mAb E53, which targets the cryptic DII fusion loop (DII-FL) epitope, neutralized prM + RVPs but not prM -RVPs 4, 6 (Fig. 2b ). As seen with most WNV antibodies 4, 7, 8 , 3 (WNV-10, WNV-57, or WNV-62) of the 4 human mAbs displayed increased neutralization potency (7-27-fold) against prM + RVPs relative to prM -RVPs (Fig. 2c-e,g ). In contrast, the IC 50 of WNV-86 was fourfold lower against prM -RVPs compared to prM + RVPs (Fig. 2f-g ), suggesting that this mAb recognizes an epitope preferentially displayed on prM -mature virions. To investigate the epitope targeted by WNV-86, we selected for neutralization escape mutations. After three serial passages in Vero cells under mAb selection pressure, WNV accumulated to high Hashed bars indicate that neutralization was not observed at the highest mAb concentration tested (10 μ g ml −1 ). The donor from which mAbs were isolated is indicated below the x axis in panels e and f. Murine mAb E16 was included as a control in panels e and f. ) in the presence of WNV-86, indicating neutralization escape ( Fig. 3a and Supplementary Fig. 6a,b) . Sequencing of escape variants from 2 independent selection experiments revealed a single nucleotide change corresponding to an amino acid substitution at E DII residue 64 (T64N), resulting in the addition of a potential N-linked glycosylation site (Fig. 3c) . WNV T64N replicated to near wild-type (WT) levels in mammalian and mosquito cell lines ( Supplementary Fig. 6e,f) . We confirmed the presence of an additional N-linked glycan on the T64N variant by SDS-PAGE and western blotting of RVP lysates with or without PNGase F treatment ( Supplementary Fig. 7a ). We next evaluated the contribution of the additional N-linked sugar to neutralization resistance by creating a panel of 13 additional RVP variants incorporating amino acid substitutions that do not introduce an extra glycan at E residue 64. Of 14 total variants, 11 (excluding T64A, T64S, T64P) resulted in a 20-fold or greater reduction in WNV-86 potency ( Supplementary  Fig. 7b,d ) but minimally impacted sensitivity to neutralization by mE16 ( Supplementary Fig. 7c,e) . These findings suggest that mutation at residue 64 directly affected WNV-86 neutralization potency, regardless of glycan occupancy.
To identify additional E residues that contribute to WNV-86 recognition, a second neutralization escape study was performed in which a WNV T64Q infectious clone variant, which displayed an intermediate sensitivity to neutralization by WNV-86 ( Supplementary Fig. 7b,d ), was passaged in the presence of antibody. Two serial passages under WNV-86 selection pressure were sufficient to select a neutralization escape virus that grew to WT levels in the presence of NAb ( Fig. 3b and Supplementary Fig. 6c,d ).
Comparison of bulk viral RNA sequences isolated from WNV T64Q passaged in the presence or absence of mAb WNV-86 identified the same single nucleotide change that resulted in a second amino acid substitution at E DII residue 208 (T208K; Fig. 3c ). As observed with WNV T64Q RVPs, when tested individually, WNV RVPs containing a T208K mutation reduced, but did not eliminate, sensitivity to neutralization by WNV-86 (Fig. 3d) . However, in combination, these two mutations abrogated WNV-86 neutralization, suggesting that mutation at both residues is required for neutralization escape from WNV-86.
To further define the epitope targeted by WNV-86, we screened 40 RVP variants encoding single, double or triple mutations at a total of 56 solvent-accessible residues throughout E DI and DII, including DII residues 64 and 208 identified in our in vitro selection experiments. Of 56 total mutations tested, 29 displayed minimal effects on neutralization sensitivity (< 2-fold change in IC 50 ), 19 modestly decreased neutralization sensitivity (2-to 4-fold increase in IC 50 ) and 6 reduced sensitivity by > 4-fold (Fig. 3e ). These six mutations are clustered in DII and, with the exception of D67N, are bounded by residues T64 and T208 (Fig. 3c) , suggesting that the binding footprint of WNV-86 lies within this region and may partially overlap with the binding site of prM of the E protein 16 . These mutations did not alter antigenicity non-specifically, as their introduction did not affect sensitivity to neutralization by mE16 (Fig. 3f) .
To evaluate the therapeutic potential of human neutralizing mAbs, five-week old C57BL/6J mice were inoculated with WNV, treated with a single dose (100 μ g; 5 mg kg -1 ) of mAb WNV-86 or WNV-10 two days post-inoculation and monitored for survival. These mAbs represented the two most potently neutralizing mAbs in our screen ( Fig. 1) , targeted non-competing epitopes, and selected for different mutations during neutralization escape studies ( Supplementary Fig. 8 ). As seen with mice treated with the therapeutic humanized murine mAb E16 (hE16) 9 , mice treated with WNV-86 were protected completely from mortality ( Fig. 4a) . In contrast, treatment with WNV-10 afforded partial protection, with 5 of 10 mice succumbing to infection by day 19. Thus, the potent neutralizing activity of WNV-86 in vitro correlated with therapeutic efficacy in vivo. Although the in vitro neutralization potency of WNV-10 was similar to that of E16 (~10 ng ml , only the latter afforded complete protection from lethal infection, suggesting that additional properties determine mAb therapeutic efficacy in vivo. Notably, administration of an LALA variant of WNV-86 that is incapable of engaging Fc receptor displayed significant, albeit slightly reduced, protection (Fig. 4b) . Moreover, both WT and 
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LALA versions of WNV-86 significantly reduced viral burden in the spinal cord and brain of infected animals (Fig. 4c,d) , suggesting that the therapeutic mechanism of WNV-86 is largely due to an ability to directly inhibit virus infection and dissemination.
In summary, we have isolated a potently neutralizing WNVspecific human mAb with therapeutic potential. WNV-86 neutralized WNV with an IC 50 that was approximately threefold lower than mAb E16, which has been shown previously to prevent mortality in WNV-infected mice 9 . Unlike E16 and most potently neutralizing mouse antibodies, WNV-86 did not recognize an epitope within DIII, consistent with the recognition pattern of recently characterized potently neutralizing human mAbs for other flaviviruses 3 . WNV-86 bound a recombinant soluble E protein, suggesting its epitope does not require a complex quaternary arrangement, which contrasts with other human neutralizing mAbs 3 . Despite its potency, competition and neutralization studies suggest that antibodies that bind this epitope are neither common nor contribute significantly to the neutralizing activity of sera ( Supplementary Fig. 9 ).
WNV-86 neutralized mature virions lacking uncleaved prM better than those retaining prM due to incomplete maturation, in contrast to many WNV antibodies characterized to date. The increased sensitivity of prM-containing virions to neutralization by many antibodies may be explained by improved epitope accessibility on E proteins arranged as heterotrimeric spikes relative to that on the E homodimers of mature virions 5 . An exception to this model may apply to antibodies targeting quaternary epitopes that span multiple E proteins 3 ; these antibodies should in theory preferentially neutralize mature virions over those that retain prM 17 . Despite our observation that WNV-86 recognition did not require a quaternary structure, structural studies are required to determine whether the accessibility of its epitope is improved on E proteins assembled as dimers on the mature virus particle, or whether residues on the opposing E protein within the dimer may contribute to WNV-86 interactions.
In vitro selection of neutralization escape virus variants and epitope mapping studies revealed a cluster of DII residues that probably a b M6I_S7G  L12V  V15L  D28G  M46L  E138S  V149H_E150Q  Y155E_S156T  A161I  R166T_S168T  A172Q  E55V_V56L  A63D  T64Q  D67N  K71D_A72S  H81T  D83V_K84E  R85E_A86Q  P88T_A89N  Q94R_V96F  I126E  V206M  G207K  T208K  R215K_E216Q  M219L  N222P  A228G_G229A_S230T  R234N  R236Q_E237F  M240V  T248K  I253V_A254V  Q258V  A261K  Q264T  L266S_A267T  I270T 
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Nature Microbiology comprise the WNV-86 epitope. Although the exact binding footprint of WNV-86 awaits structural studies, the DII epitope identified by our mapping studies appears distinct from that within the DI-DII hinge recognized by some strongly neutralizing human mAbs [18] [19] [20] . Although E protein residue 64, which strongly impacted WNV-86 recognition, is highly conserved among WNV strains 21 , we observed strain-dependent neutralization sensitivity, with the more distantly related African lineage II WNV strain WN 956 D117 3B displaying reduced sensitivity (Supplementary Fig. 10) . Notably, the sequences of this and other lineage II strains differ at both E protein positions 64 and 208, shown here to be important for WNV-86 recognition.
As seen with mAb E16, the in vitro neutralization potency of WNV-86 correlated with in vivo therapeutic efficacy. In contrast, despite its potent neutralizing activity in vitro, when administered as a single dose post-exposure, WNV-10 prevented mortality in only 50% of mice. Reduced in vivo efficacy of WNV-10 may reflect the existence of a measurable fraction of virions resistant to neutralization or an inability to neutralize at a post-attachment step ( Supplementary Figs. 1 and 4) . Other factors may uniquely contribute to in vivo protection. For example, although administration of WNV-86 resulted in significant protection independently of Fc-mediated functions, the protective efficacy of E16 was diminished in mice lacking Fcγ receptors 9 . Understanding whether the cellular mechanism of antibody neutralization contributes to therapeutic efficacy awaits further studies.
Methods
Human subjects. Blood samples were obtained in 2014 from adult subjects with history of symptomatic laboratory-confirmed WNV infection during the 2012 West Nile encephalitis outbreak in Dallas, Texas. The studies were approved by the Institutional Review Board of Vanderbilt University Medical Center; samples were collected after written informed consent was obtained by the Vanderbilt Clinical Trials Center.
Generation of anti-E mAbs.
Peripheral blood mononuclear cells were isolated from heparinized blood by gradient centrifugation after layering on Ficoll Histopaque, and cryopreserved in the vapour phase of liquid nitrogen until use. B cells from donors 865, 866 and 870 were transformed by infection with Epstein Barr virus obtained from the supernatant of cultured B95.8 cotton-top tamarin lymphoblastoid line (ATCC). The transformation medium contained 2.5 µ g ml -1 TLR agonist CpG (phosphorothioate-modified oligodeoxynucleotide ZOEZOEZZZZZOEEZOEZZZT, Life Technologies), 10 µ M Chk2 inhibitor (Sigma) and 10 µ g ml -1 cyclosporine A (Sigma). B cells were plated in 384-well culture plates and cultured for 7 d and then expanded into 4 96-well culture plates containing CpG, Chk2 inhibitor and irradiated heterologous human peripheral blood mononuclear cells to serve as feeder layers for the growth of lymphoblastoid cell line clusters. After an additional 3 d of culture, the supernatants were screened for binding to recombinant soluble WNV E protein by enzyme-linked immunosorbent assay (ELISA). Approximately 5 µ l supernatant from each well of transformed B cell cultures (in a total assay volume of 50 µ l) was added to wells coated with 2 µ g ml -1 recombinant WNV E protein. The bound antibodies were detected using alkaline phosphatase-conjugated goat anti-human Ig (γ -chain specific) (Southern Biotech). The frequency of WNV E protein-specific Epstein Barr virus-transformed B cells was similar for the three donors (0.9% for 865; 1.1% for 866; and 0.7% for 870).
Cells from wells positive for binding to WNV E were subjected to electrofusion with HMMA2.5 myeloma cells 22 . The fused cells then were cultured in a selective medium containing 100 µ M hypoxanthine, 0.4 µ M aminopterin, 16 µ M thymidine (HAT Media Supplement, Sigma HO262) and 7 µ g m -1 ouabain (Sigma O3125) and incubated for 14-18 d before screening hybridomas for antibody production by ELISA using recombinant WNV E protein. Cells from positive wells were cloned by sorting live unlabelled single cells into 384-well plates using a FACSAria III fluorescence-activated cell sorter (Becton Dickinson), cultured for about 14 d and screened for specific antibody production by ELISA using WNV E protein. For expression of antibodies from hybridoma clones, cells were cultured in serum-free Mice administered WNV-specific mAb hE16 or isotype-control mAb hCHK-152 were used as positive or negative controls, respectively. Data were pooled from two experiments (n = 10 per group). The indicated P value was obtained from a onesided log-rank test. b, To address the contribution of effector functions in protection in mice following the administration of WNV-86, a LALA variant of this antibody was administered to 5-week-old C57BL/6 mice (100 µ g per mouse, n = 10) 2 d following inoculation and they were monitored for survival. The indicated P values were obtained from a one-sided log-rank test. c,d, At day 8 post-infection, spinal cords and brains were collected after extensive perfusion, and WNV levels were titrated by plaque assay on Vero cells. Dashed line indicates limit of detection, and bars indicate the median. p.f.u., plaque-forming units. Data were pooled from two independent experiments for WNV-86 (n = 9), WNV-86 LALA (n = 10) and hCHK-152 (n = 7; 3 mice died in this group before tissue collection), and analysed using an ANOVA with Dunn's post-test.
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Nature Microbiology medium, Hybridoma SFM (Life Technologies), for 21 d. Antibodies were collected from the supernatants by affinity chromatography on HiTrap MabSelect SuRe columns (Life Technologies) according to the manufacturer's instructions. Antibodies eluted from affinity columns were concentrated using Amicon centrifugal filters (Millipore). Antibody heavy and light chain variable genes for one hybridoma clone (WNV-86) were amplified by RT-PCR from hybridoma cell RNA and then sequenced by Sanger sequencing. Complementary DNAs encoding the WNV-86 antibody variable genes were synthesized and cloned into expression vectors for (1) Fab, (2) WT IgG1 or (3) IgG1 with an LALA variant Fc region, and recombinant antibodies expressed in 293F cells.
Cells.
Raji B lymphoblast cells (ATCC) engineered to stably express DC-SIGNR (Raji-DCSIGNR) 23 were cultured in RPMI 1640 medium containing Glutamax (Invitrogen) supplemented with 7% foetal bovine serum (Invitrogen) and 100 U ml -1 penicillin-streptomycin (Invitrogen). HEK-293T (ATCC), Vero (ATCC) and C6/36 (ATCC) cells were maintained in DMEM containing 25 mM HEPES (Invitrogen) supplemented with 7% foetal bovine serum and 100 U ml -1 penicillin-streptomycin. Raji-DCSIGNR, HEK-293T and Vero cells were maintained at 37 °C in the presence of 7% CO 2 . C6/36 cells were maintained at 28 °C in the presence of 7% CO 2. Cell lines used in this study were not authenticated or tested for mycoplasma contamination before use in these studies. Cell banks from which these cells were grown were shown to be mycoplasma-free using the Universal Mycoplasma Detection Kit (ATCC). DCSIGNR expression on stable Raji cells was confirmed using mouse anti-human DC-SIGNR/CD299 (R&D Systems MAB162 clone 120604; RBO1; lot: DZV0215051; 10 µ g ml -1 ).
Generation of plasmids encoding E protein variants. We used a previously described expression vector encoding the structural genes (C-prM-E) of the WNV NY99 strain 15 as a template for site-directed mutagenesis using the Pfu Ultra DNA polymerase system (Agilent Technologies). PCR cycling parameters were: 1 cycle of 95 °C for 1 min; 18 cycles of 95 °C for 50 s, 60 °C for 50 s and 68 °C for 9 min; and 1 cycle of 68 °C for 7 min. Following digestion with DpnI (New England Biolabs) for 3 h at 37 °C, PCR products were used to transform Stbl2 cells (Invitrogen) and propagated at 30 °C. After confirming the presence of the desired mutation by sequencing, the entire C-prM-E region was sequenced to ensure that no additional mutations were present.
Production of RVPs.
RVPs were produced by cotransfection of a plasmid expressing a WNV subgenomic replicon in which the structural genes have been replaced with GFP, and a plasmid encoding the structural genes, as described previously 15, 24, 25 . To prepare mature RVPs with increased efficiency of prM cleavage, RVPs were produced by cotransfecting plasmids encoding the replicon, structural genes and human furin at a 1:3:1 ratio by mass. Immature RVPs with decreased prM cleavage efficiency were produced in cells treated with 20 mM NH 4 Cl, as described previously 4 .
Production of fully infectious WNV.
A DNA fragment encoding WT WNV structural genes or WNV structural genes encoding a mutation at E residue 64 was ligated into a GFP-expressing WNV "backbone" replicon plasmid (pWNV-GFP-backbone V3), and transfected directly into HEK-293T cells to generate infectious virus particles, as described previously 26 . Cells were incubated at 37 °C in the presence of 7% CO 2 . Viral supernatant was collected at 3 d post-transfection, filtered using a 0.22 μ m filter (Millipore) and stored at -80 °C.
Determination of virus titre. Virus-containing supernatant was serially diluted twofold in a total volume of 100 μ l and used to infect 5 × 10 4 Raji-DCSIGNR cells in an equal volume at 37 °C. Cells were fixed in 1.8% paraformaldehyde at 48 h or 16 h following infection by RVPs or fully infectious virus, respectively, and GFP-positive cells were enumerated using flow cytometry (BD FACSCalibur). Infectious titre was calculated using the linear portion of the resulting dose-response infectivity curve using the following formula: Infectious units per virus volume = (percentage of GFP-positive cells) × (dilution factor) × (number of cells).
Neutralization assays. RVP or fully infectious virus stocks were diluted to ~5-10% infectivity and incubated with serial dilutions of mAbs for 1 h at room temperature before the addition of Raji-DCSIGNR cells. All infections were performed in duplicate at 37 °C. At 48 h (RVP) or 16 h (fully infectious virus) post-infection, infectivity was measured as a percentage of GFP-positive cells by flow cytometry (BD FACSCalibur). Antibody dose-response curves were analysed using nonlinear regression with a variable slope (GraphPad Prism v 6.0 g, GraphPad Software Inc.) to estimate the reciprocal serum dilution (NT 50 ) or concentration of antibody (IC 50 ) required to inhibit infection by 50%.
RVP binding assays.
Standard preparation WNV RVPs were incubated with sixfold serial dilutions of mAbs for 1 h at 37 °C to allow binding to reach equilibrium. Raji-DCSIGNR cells were added and incubated with the RVPantibody complexes for 3.5 h at 37 °C. As a negative control, Raji-DCSIGNR cells were incubated with anti-DCSIGNR antibody (detailed above) at 30 °C for 30 min before addition. After incubation, cells were washed to remove unbound RVPs. Half of the cells were moved to a new 96-well plate in fresh media and incubated at 37 °C for 48 h. Infectivity was measured by flow cytometry as described previously. The remaining cells were lysed using the QIAshredder kit (Qiagen) and total RNA was isolated using the RNeasy Mini kit (Qiagen), in accordance with the manufacturer's instructions. The relative amount of WNV RNA was determined by quantitative reverse-transcriptase PCR using known copy numbers of the WNV replicon plasmid to generate a standard curve. Additional experiments (not shown) were performed to ensure that, at 3.5 h, genomic RNA replication in infected cells does not impact WNV RNA copy number. The data were analysed using nonlinear regression with a variable slope (GraphPad Prism v 6.0 g, GraphPad Software Inc.).
Selection of neutralization escape variants.
Fully infectious GFP-expressing WNV 26 was incubated with mAb WNV-86 at a concentration that was approximately 200-fold greater than its IC 50 (0.6 μ g ml -1 for WT; 2 μ g -1 ml -1
for WNV T64Q) in a total volume of 2 ml for 30 min at 37 °C, followed by duplicate infection of preplated Vero cells (8.5 × 10 5 per well) in a 6-well dish at a multiplicity of infection (MOI) of 0.1. After 3-4 d of infection at 37 °C, continuous viral replication and antibody selection pressure were maintained by serial passaging of virus supernatant diluted 1:10 in medium with or without WNV-86 in a total volume of 2 ml and incubating for 30 min at 37 °C before addition to fresh Vero cells. The remaining volume of virus supernatant was aliquoted and stored at -80 °C until further use. Replication of antibody escape viral variants was monitored by visually inspecting cells for GFP expression and confirmed by inoculating Raji-DCSIGNR cells with an aliquot of the virus supernatant (serially diluted twofold) in the presence or absence of a neutralizing concentration (2 μ g ml -1 ) of WNV-86, and by neutralization assays as described above. Following confirmation of mAb escape, viral RNA was isolated from a 50-μ l aliquot of viral supernatant (adjusted to 140 μ l in RNase-free water) using the QIAamp viral RNA mini kit (Qiagen) according to the manufacturer's instructions. cDNA encoding WNV structural genes was amplified using the SuperScript III One-Step RT-PCR system (Invitrogen). The structural genes were sequenced directly from the gel-purified PCR product and were compared to the structural gene sequence of WNV passaged in parallel in the absence of antibody to identify mAb-induced escape mutations.
MAb binding to recombinant E proteins. mAb binding to WNV was measured by ELISA, as described previously 27 . Briefly, recombinant WNV E ectodomain or DIII fragment was diluted to 5 μ g ml -1 in 0.1 M sodium carbonate buffer (pH 9.3) and adsorbed on 96-well Nunc MaxiSorp microtitre plates (ThermoFisher Scientific) overnight at 4 °C. After blocking with PBS containing 2% bovine serum albumin and 0.05% Tween 20 (PBS-BT) for 1 h at 37 °C, threefold serial dilutions of antibody in PBS-BT were incubated for 1 h at room temperature. Plates were washed with PBS plus 0.05% Tween 20 and incubated with biotin-conjugated goat anti-mouse IgG (1 μ g ml -1 ; Sigma-Aldrich SAB4600004) for 1 h at room temperature. After washing, all plates were incubated with streptavidin-horseradish peroxidase (2 μ g ml -1
; Zymed) for 1 h at room temperature and developed with tetramethylbenzidine substrate (Dako). After the addition of 1 N H 2 SO 4 , the optical density at 450 nm was measured. Best-fit lines were fit using GraphPad Prism v 6.0 g (GraphPad Software, Inc).
Determining E protein glycosylation status. RVP-containing supernatant (1.5 ml) from transfected cells in a 6-well plate was concentrated and partially purified by microcentrifugation (14,000 × g overnight at 4 °C) through a 20% sucrose cushion (0.25 ml per 1.5 ml RVP). The resulting RVP pellet was resuspended and lysed in TNE buffer (50 mM Tris, 140 mM NaCl, 5 mM EDTA, pH adjusted to 7.4) containing 1% Triton-X100 followed by digestion with PNGase F (New England Biolabs) for 3 h at 37 °C. Undigested and PNGase F-digested E proteins in RVP lysates were detected by SDS-PAGE and western blot analysis using mouse mAb 4G2 (1 μ g ml -1 ; Novus Biologicals NBP2-52666 clone D1-4G2-4-15). IRDye 800CW goat anti-mouse IgG (LI-COR Biosciences 925-32210) diluted 1:2,500 was used as a secondary antibody. Protein bands were visualized using the Odyssey infrared imaging system (LI-COR Biosciences).
Mouse experiments. Five-week-old C57BL/6J male mice (Jackson Laboratories, 000644) were inoculated subcutaneously with 10 2 focus forming units (FFUs) of WNV NY99 after anaesthetization with xylazine and ketamine. Two d postinfection, mice were given 100 μ g mAb (~5 mg kg Statistical analysis. All data were analysed in GraphPad Prism v 6.0g (GraphPad Software Inc.) and expressed as mean or median values and their range (two data points) or standard error of the mean (three or more data points). P values were calculated using paired t-tests, ANOVA or the log-rank test, with post hoc corrections for multiple comparisons, as indicated in the figure legends.
Letters
Nature Microbiology
Ethical compliance. We have complied with all relevant ethical regulations for research animals and human research participants.
Repoting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Additional data sets generated and/or analysed during the current study are available from the corresponding authors on reasonable request. This study used deidentified human PBMCs as starting material, however it was not designed as a clinical study per se, so there were no projections or power calculations a priori, as this is not relevant to our approach. The goal of our study was to isolate and characterize potently neutralizing monoclonal antibodies with novel properties. We studied PBMC samples from de-identified survivor PBMCs unitl we identified potent neutralizing monoclonal antibodies. Our sample size of 13 individuals with history of laboratory-confirmed WNV infection was sufficient for isolating clones of interest.
Data exclusions
Describe any data exclusions. No data were excluded from the analyses
Replication
Describe whether the experimental findings were reliably reproduced.
Findings presented were based on at least two independent experiments, as stated in the figure legends.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
In Figure 4 , 10 mice were allocated into each treatment group across two independent experiments
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not used during data collection and/or analysis as the clinical outcomes (survival and death) were not amenable to subjective bias of interpretation.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
GraphPad Prism v6.0g
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Plasmids used throughout the study to create reporter virus particles are available upon request. Please contact Ted Pierson; piersontc@mail.nih.gov
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Human antibodies used were generated as part of our study using previously described methods (Smith SA c. Report whether the cell lines were tested for mycoplasma contamination.
Cell lines were not tested for mycoplasma prior to these experiments. Cell banks from which these cells were grown were are mycoplasma-free as evaluated using the Universal Mycoplasma Detection Kit (ATCC).
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used
